Edesa Biotech (EDSA) Reaffirms 2026 Clinical Study Timeline for Vitiligo Treatment [Yahoo! Finance]
Edesa Biotech, Inc. - Common Shares (EDSA)
Company Research
Source: Yahoo! Finance
Edesa Biotech Inc. (NASDAQ: EDSA ) is one of the unstoppable stocks that could double your money. On March 26, Edesa reaffirmed that enrollment for its Phase 2 clinical study of EB06, which is a treatment for moderate-to-severe nonsegmental vitiligo, is on track to begin in mid-2026. The company has selected JSS Medical Research as its clinical research organization and has initiated outreach to potential clinical sites. Recruitment is expected to start at investigational sites in Canada, following the approval of the company's clinical trial application. The upcoming study will evaluate the safety and efficacy of EB06, a monoclonal antibody designed to target the chemokine CXCL10, which plays a critical role in the destruction of skin pigment cells. By neutralizing this protein, EB06 aims to prevent and reverse the depigmentation associated with vitiligo. The CEO emphasized that the trial design has been refined through discussions with key opinion leaders to address the significa
Show less
Read more
Impact Snapshot
Event Time:
EDSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EDSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EDSA alerts
High impacting Edesa Biotech, Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
EDSA
News
- Acute Respiratory Distress Syndrome Clinical Trial Pipeline Shows Potential with Active Contributions from 40+ Key Companies | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Edesa Biotech (EDSA) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=EDSA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" to "MarketBeat
- Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit [Yahoo! Finance]Yahoo! Finance
- Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit [TheStreet.com]TheStreet.com
- Edesa Biotech Invited for Oral Showcase at Respiratory Innovation SummitGlobeNewswire
EDSA
Sec Filings
- 4/10/26 - Form 4
- 4/3/26 - Form ARS
- 4/3/26 - Form DEFA14A
- EDSA's page on the SEC website